SCHEMBL21152317

SCHEMBL21152317

COC(=O)c1sc(F)cc1CN

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.42
MAPT P10636 5/20 0.39
HSD17B10 Q99714 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.39
LOXL2 Q9Y4K0 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 1/20 0.37
DPP4 P27487 2/20 0.37
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
ALOX15 P16050 2/20 0.36
KDM4E B2RXH2 4/20 0.36
MEN1 O00255 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.36
NPC1 O15118 2/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21152318 0.83 IKBKB (0.42) IKBKBMAPTHSD17B10KMT2ATSHR
SCHEMBL21152503 0.75 MAPT (0.44) IKBKBMAPTHSD17B10KMT2ATSHR
SCHEMBL1495847 0.70 LOXL2 (0.54) MAPTHSD17B10KMT2ALOXL2DPP4
SCHEMBL21711836 0.70 LOXL2 (0.46) MAPTLOXL2L3MBTL1POLBDPP4
SCHEMBL160615 0.69 KMT2A (0.54) MAPTKMT2ATSHRLOXL2L3MBTL1
Hydrochloric Acid SCHEMBL12499887 0.69 LOXL2 (0.53) MAPTHSD17B10LOXL2DPP4ALDH1A1
SCHEMBL19436409 0.68 IKBKB (0.43) IKBKBMAPTHSD17B10KMT2ATSHR
SCHEMBL16881270 0.68 DPP4 (0.43) MAPTHSD17B10TSHRLOXL2L3MBTL1
SCHEMBL16812304 0.67 KDM4E (0.50) MAPTHSD17B10TSHRLOXL2L3MBTL1
SCHEMBL17083284 0.67 LOXL2 (0.54) MAPTHSD17B10KMT2ALOXL2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3735404-B1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF SEAL ROCK THERAPEUTICS INC (US) 2023-11-29 EP disclosed
US-20210213006-A1 METHODS OF TREATING NEURODEGENERATIVE DISEASES Seal Rock Therapeutics, Inc. 2021-07-15 US disclosed
WO-2020046975-A1 METHODS OF TREATING NEURODEGENERATIVE DISEASES Seal Rock Therapeutics, Inc. (US) 2020-03-05 WO disclosed
WO-2019136025-A1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF Seal Rock Therapeutics, Inc. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210213006-A1 METHODS OF TREATING NEURODEGENERATIVE DISEASES SNCA, MAPT, HTT IKBKB 840/4885MAPT 2/4885HSD17B10 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.